Northern Trust Corp Boosts Stock Position in Krystal Biotech, Inc. (NASDAQ:KRYS)

Northern Trust Corp raised its position in shares of Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 262,263 shares of the company's stock after purchasing an additional 23,572 shares during the period. Northern Trust Corp owned 0.91% of Krystal Biotech worth $41,086,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in KRYS. Wilmington Savings Fund Society FSB bought a new stake in Krystal Biotech in the 3rd quarter valued at about $40,000. Covestor Ltd boosted its holdings in Krystal Biotech by 972.7% during the 4th quarter. Covestor Ltd now owns 708 shares of the company's stock valued at $111,000 after acquiring an additional 642 shares during the period. Avanza Fonder AB purchased a new position in Krystal Biotech in the 4th quarter worth approximately $119,000. KBC Group NV grew its holdings in shares of Krystal Biotech by 46.3% in the fourth quarter. KBC Group NV now owns 939 shares of the company's stock worth $147,000 after purchasing an additional 297 shares during the last quarter. Finally, Blue Trust Inc. boosted its position in Krystal Biotech by 74.4% during the 4th quarter. Blue Trust Inc. now owns 1,015 shares of the company's stock valued at $159,000 after buying an additional 433 shares during the period. 86.29% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on KRYS. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. HC Wainwright reissued a "buy" rating and set a $240.00 price objective on shares of Krystal Biotech in a research report on Tuesday, May 6th. Chardan Capital reaffirmed a "buy" rating and issued a $219.00 target price on shares of Krystal Biotech in a report on Wednesday, May 7th. Cantor Fitzgerald reiterated an "overweight" rating and set a $215.00 price target on shares of Krystal Biotech in a report on Thursday, February 20th. Finally, Citigroup boosted their price objective on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a "neutral" rating in a report on Thursday, February 20th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $218.63.

Krystal Biotech Stock Performance

KRYS traded down $5.20 during trading on Wednesday, reaching $129.33. 141,908 shares of the company traded hands, compared to its average volume of 298,937. The company has a market cap of $3.74 billion, a P/E ratio of 43.25 and a beta of 0.79. The firm has a fifty day simple moving average of $169.86 and a 200 day simple moving average of $169.51. Krystal Biotech, Inc. has a 12-month low of $128.00 and a 12-month high of $219.34.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $88.18 million for the quarter, compared to analysts' expectations of $98.66 million. As a group, sell-side analysts expect that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Suma Krishnan sold 25,000 shares of the business's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total value of $4,444,750.00. Following the completion of the sale, the insider now owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total transaction of $131,415.00. Following the transaction, the chief accounting officer now directly owns 12,604 shares in the company, valued at approximately $2,208,472.88. The trade was a 5.62% decrease in their ownership of the stock. The disclosure for this sale can be found here. 13.70% of the stock is currently owned by corporate insiders.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).